Using a new synthetic progestin to prevent preterm labor and fetal inflammation
Drug repurposing of a novel synthetic progestin for the prevention of preterm labor and fetal inflammation
This study is looking at a new medication called R5020 to see if it can help prevent early labor and inflammation in pregnant women who might have infections, using a special animal model to test how well it works.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11196722 on NIH RePORTER |
What this research studies
This research investigates the use of a novel synthetic progestin, R5020, to prevent preterm labor and fetal inflammation caused by intrauterine infections. The study utilizes a new animal model involving preterm Rhesus macaques to simulate the conditions of intrauterine infection and assess the effectiveness of R5020 in reducing inflammation and preventing labor. By understanding the mechanisms of inflammation and the role of specific enzymes, the research aims to provide a more effective treatment option for pregnant individuals at risk of preterm labor.
Who could benefit from this research
Good fit: Ideal candidates for this research are pregnant individuals at risk of preterm labor due to intrauterine infections.
Not a fit: Patients who are not pregnant or those whose preterm labor is not related to intrauterine infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option for preventing preterm labor and protecting fetal health.
How similar studies have performed: Previous research has shown promise in drug repurposing for similar conditions, but the specific use of R5020 in this context is novel.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Kallapur, Suhas — University of California Los Angeles
- Study coordinator: Kallapur, Suhas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.